Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SEC's website at www.sec.gov or by request at Dawson James Securities, Inc. by e-mailing placements@djsiny.com.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of OncoSec's common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's cu
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
(Date:4/22/2014)... Jerusalem, April 22, 2014 -- In parallel with modern man ... of humans with whom we lived side by side, such ... Yet only Homo sapiens survived. What was it ... The truth is that little is known about our unique ... it contributed to the fact that we are the only ...
(Date:4/22/2014)... exposed to trauma, illness, alcohol or other drug abuse, ... brain cells that can go awry and activate conditions ... of autism. , Until now, it has been unclear ... a developing brain. Past studies have shown that when ... abuse or she experiences some trauma or illness, her ...
(Date:4/22/2014)... be influenced by low exposure to testosterone in the ... how men,s testosterone levels may be determined before they ... of the hormone than others is important because testosterone ... the hormone have been linked to obesity, diabetes and ... responsible for producing testosterone in adults known as ...
(Date:4/22/2014)... stroke intervention researchers have been informed that the National ... National Institutes of Health, will award an $8 million ... of an experimental drug for stroke. , The ... tissue plasminogen activator, or rtPA the "clot-busting" drug ... In laboratory rodent studies, 3K3A-APC, used in combination with ...
(Date:4/22/2014)... 22, 2014) Older parents are more likely to ... (ASD) than are younger parents. A recent study from ... in Philadelphia and Karolinska Institute in Sweden provides more ... varies between mothers, and fathers, ages, and found that ... and intellectual disability is larger for older parents., In ...
Breaking Medicine News(10 mins):Health News:What gave us the advantage over extinct types of humans? 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:Child's autism risk accelerates with mother's age over 30 2Health News:Child's autism risk accelerates with mother's age over 30 3
... Sint Antonius Hospital in Nieuwegein, the Netherlands say that ... air and belch more frequently, air swallowing does not ... to test whether air swallowing had any role in ... esophagus of 12 people with GERD and 12 healthy ...
... new study says that drinking alcohol is linked to ... of drinking//. ,"Social drinking builds social capital," ... Jose State University. "Social drinkers are out networking, ... result in bigger paychecks." ,The researchers said that ...
... Rosiglitazone, an oral drug used to reduce the amount of sugar ... a study.// ,Type 2 diabetes occurs when people cannot ... is the essential hormone that helps sugars to be turned into ... regulate their use of glucose are at high risk of Type ...
... — the grocery store — can help improve and ... a new study conducted in the Marshall// Islands. By ... habits, the researchers were able to foster an increase ... ,“Diet-related chronic diseases are at epidemic proportions, ...
... already suffered a stroke could run a further risk of ... findings of a new study. Recurrent// strokes could also disable ... Ruland, of the University at Chicago said” Stroke incidence and ... whites. Part of this risk may be explained by a ...
... confirmed in Wisconsin, the outbreak of the disease is ... One person has succumbed to the disease in the ... of the 30 cases have needed hospital admission and ... the patients are women. ,The places ...
Cached Medicine News:Health News:‘Healthy Stores’ Program Boosts Demand for Better Food in Marshall Islan 2
Lorgnette pinhole occluder...
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Medicine Products: